Shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) have earned an average recommendation of “Buy” from the fifteen analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $62.00.
A number of analysts recently issued reports on ARWR shares. HC Wainwright restated a “buy” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 24th. BidaskClub downgraded Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 12th. TheStreet downgraded Arrowhead Pharmaceuticals from a “c-” rating to a “d+” rating in a research report on Thursday, September 3rd. Chardan Capital restated a “buy” rating and issued a $81.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, July 29th. Finally, ValuEngine upgraded Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd.
ARWR stock opened at $47.43 on Thursday. The firm has a fifty day moving average price of $40.54 and a 200 day moving average price of $37.10. Arrowhead Pharmaceuticals has a fifty-two week low of $19.51 and a fifty-two week high of $73.72. The firm has a market cap of $4.85 billion, a PE ratio of -189.72 and a beta of 1.67.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $27.38 million during the quarter, compared to analysts’ expectations of $38.76 million. Arrowhead Pharmaceuticals had a negative net margin of 19.75% and a negative return on equity of 5.65%. As a group, research analysts anticipate that Arrowhead Pharmaceuticals will post -0.48 EPS for the current fiscal year.
In other news, CEO Christopher Richard Anzalone sold 50,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $41.35, for a total transaction of $2,067,500.00. Following the completion of the sale, the chief executive officer now directly owns 2,655,237 shares in the company, valued at $109,794,049.95. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.00% of the stock is currently owned by company insiders.
Several large investors have recently added to or reduced their stakes in ARWR. Two Sigma Advisers LP lifted its holdings in Arrowhead Pharmaceuticals by 6.0% in the second quarter. Two Sigma Advisers LP now owns 663,100 shares of the biotechnology company’s stock valued at $28,639,000 after acquiring an additional 37,600 shares during the period. Neuberger Berman Group LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth approximately $3,463,000. Handelsbanken Fonder AB acquired a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth approximately $682,000. Nuveen Asset Management LLC raised its stake in shares of Arrowhead Pharmaceuticals by 13.9% during the 2nd quarter. Nuveen Asset Management LLC now owns 781,001 shares of the biotechnology company’s stock worth $33,732,000 after buying an additional 95,604 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Arrowhead Pharmaceuticals by 3.8% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 729,508 shares of the biotechnology company’s stock worth $31,508,000 after buying an additional 26,482 shares during the period. Institutional investors and hedge funds own 66.34% of the company’s stock.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Featured Story: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.